Olema Oncology is a clinical-stage biopharmaceutical company developing novel therapies to transform treatment for metastatic breast cancer and beyond. Backed by Lightspeed.
About the role
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. Found on 1752vc Careers, the job board for startup and VC roles.
What they're looking for
- Set the commercial supply strategy for palazestrant, including network design, capacity and second-source planning, and the launch inventory build (including at-risk manufacturing and packaging decisions)
- Own the commercial supply budget, COGS inputs, supply cost KPIs and tariff exposure in partnership with Finance
- Lead supply-side launch readiness from NDA submission through PDUFA and market entry, maintain the launch risk register and present status, risks and mitigation options to executive leadership
- Negotiate and own commercial supply agreements, run quarterly business reviews and performance metrics across DS, DP, packaging and logistics partners
- Manage CDMO production schedules day to day, resolving issues and escalating as needed to protect supply
- Oversee commercial packaging and labeling vendors, including artwork readiness, labeling specifications, and batch documentation
More about this role
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to...
Browse similar: Startup jobs